Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

被引:113
|
作者
Freites Nunez, Dalifer D. [1 ,2 ]
Leon, Leticia [1 ,2 ,3 ]
Mucientes, Arkaitz [1 ,2 ]
Rodriguez-Rodriguez, Luis [1 ,2 ]
Font Urgelles, Judit [4 ]
Madrid Garcia, Alfredo [1 ,2 ]
Colomer, Jose, I [1 ,2 ]
Jover, Juan A. [4 ,5 ]
Fernandez-Gutierrez, Benjamin [4 ]
Abasolo, Lydia [1 ,2 ]
机构
[1] Fdn Invest Biomed Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[2] Fdn Invest Biomed Hosp Clin San Carlos, IDISSC, Madrid, Spain
[3] Univ Camilo Jose Cela, Dept Hlth & Educ, Madrid, Spain
[4] Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[5] Univ Complutense Madrid, Med Dept, Madrid, Comunidad De Ma, Spain
关键词
CORONAVIRUS;
D O I
10.1136/annrheumdis-2020-217984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. Methods An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. Results The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. Conclusion Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
引用
收藏
页码:1393 / 1399
页数:7
相关论文
共 50 条
  • [1] Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'
    Aydin, Sibel Zehra
    Hepworth, Elliot
    Tugwell, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03) : E69 - E69
  • [2] Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'
    Schulze-Koops, Hendrik
    Skapenko, Alla
    Krause, Andreas
    Krueger, Klaus
    Lorenz, Hanns-Martin
    Sewerin, Philipp
    Specker, Christof
    Wagner, Ulf G.
    Voormann, Anna
    Mueller-Ladner, Ulf
    Voll, Reinhard E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01)
  • [3] Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al
    Freites Nunez, Dalifer Dayanira
    Leon, Leticia
    Mucientes, Arkaitz
    Rodriguez-Rodriguez, Luis
    Font Urgelles, Judit
    Madrid Garcia, Alfredo
    Colomer, Jose Ignacio
    Jover, Juan A.
    Fernandez-Gutierrez, Benjamin
    Abasolo, Lydia
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03)
  • [4] Response to: 'Correspondence on `Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al
    Nunez, Dalifer Dayanira Freites
    Leon, Leticia
    Mucientes, Arkaitz
    Rodriguez-Rodriguez, Luis
    Urgelles, Judit Font
    Garcia, Alfredo Madrid
    Colomer, Jose Ignacio
    Jover, Juan A.
    Fernandez-Gutierrez, Benjamin
    Abasolo, Lydia
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01)
  • [5] RISK OF COVID-19 IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES
    不详
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2021, 125 (01): : 41 - 41
  • [6] The COVID-19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases
    Chen, Jiali
    Cai, Wenxin
    Liu, Tian
    Zhou, Yunshan
    Jin, Yuebo
    Yang, Yue
    Chen, Shi
    Tang, Kun
    Li, Chun
    RHEUMATOLOGY & AUTOIMMUNITY, 2022, 2 (02): : 82 - 91
  • [7] Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
    Zheng, Yi-Qing
    Li, He-Jun
    Chen, Ling
    Lin, Shun-Ping
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [8] Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)
    Lam, Gordon
    Laster, Andrew
    McCarter, Sarah
    Gladue, Heather
    Kashif, Ahmad
    Siceloff, Erin
    Lackey, Victoria
    Robertson, Cheryl
    Toci, Ashley
    Calabrese, Leonard
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2013 - 2016
  • [9] Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
    Yi-Qing Zheng
    He-Jun Li
    Ling Chen
    Shun-Ping Lin
    Scientific Reports, 12
  • [10] Evolution of COVID-19 in patients with autoimmune rheumatic diseases
    Pang, Rongrong
    Zhao, Jun
    Gan, Zhenhua
    Hu, Zhiliang
    Xue, Xiang
    Wu, Yanjun
    Qiao, Qinghua
    Zhong, Aifang
    Xia, Xinyi
    Liao, Hui
    Wang, Zhihua
    Zhang, Libo
    AGING-US, 2020, 12 (23): : 23427 - 23435